News about Global Pharma

Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH)

Lonza has received Swissmedic approval for its new state-of-the-art aseptic filling line in Stein (CH), designed for biologics and highly potent products, including antibody-drug conjugates (ADCs).

Global Pharma | 10/10/2025 | By Dineshwori |  261

Novo Nordisk to Acquire Akero Therapeutics Alongside Promising MASH Therapy Efruxifermin

Danish pharma giant Novo Nordisk has signed a definitive agreement to acquire Akero Therapeutics, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for serious metabolic diseases.

Global Pharma | 10/10/2025 | By Dineshwori |  397

Jubilant HollisterStier Expands Spokane Facility with USD 132 Million Sterile Fill & Finish Line Launch

Jubilant HollisterStier LLC (JHS) — a wholly owned subsidiary of Jubilant Pharmova and a leading North American contract manufacturer specialising in sterile injectables — has launched a new Sterile Fill & Finish line, its third at the Spokane manufacturing facility in Washington, USA.

Global Pharma | 10/10/2025 | By Dineshwori |  295

Thermo Fisher Launches Molecular Microscope to Assess Lung Transplant Rejection

Thermo Fisher’s new Molecular Microscope Diagnostic System for Lung (MMDx Lung) leverages the power of Machine Learning (ML) to profile gene expression data from lung biopsies, comparing each new sample to a reference set of over 896 lung biopsies.

Global Pharma | 10/10/2025 | By Dineshwori |  190

Boehringer Ingelheim's Jascayd Receives US FDA Approval for Oral Treatment Option for Adults with IPF

Jascayd is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a novel mechanism of action that exerts both antifibrotic and immunomodulatory effects, thereby slowing the decline in lung function in IPF patients.

Global Pharma | 10/10/2025 | By Dineshwori |  510

XenoTherapeutics Completes Takeover of Canada's ESSA Pharma

Canada-based ESSA Pharma has announced the completion of its acquisition by XenoTherapeutics, a US-based research foundation focused on advancing xenotransplantation therapies.

Global Pharma | 10/10/2025 | By Dineshwori |  1335

Samsung Biologics Launches ExellenS Framework to Standardize and Accelerate Biomanufacturing Operations

By deploying the ExellenS framework across its manufacturing network—with standardised designs, unified processes, and advanced digital integration—Samsung Biologics ensures plant equivalency, operational speed, and seamless manufacturing continuity.

Global Pharma | 10/10/2025 | By Dineshwori |  358

Complement Therapeutics Receives US FDA Clearance to Begin Opti-GAIN Phase-I/II Trial of CTx001 in Patients with GA Secondary to AMD

CTx001, an AAV-based gene therapy, delivers a mini-CR1 protein to modulate complement pathways and address Geographic Atrophy (GA), an advanced dry AMD causing irreversible vision loss.

Global Pharma | 09/10/2025 | By Dineshwori |  195

Turbine Partners with AstraZeneca to Accelerate Antibody-Drug Conjugate Discovery

Turbine, a leading company specialising in virtualising biological experiments through artificial intelligence (AI), has announced a new collaboration with AstraZeneca to enhance the discovery of antibody-drug conjugates (ADCs).

Global Pharma | 09/10/2025 | By Dineshwori |  328

CND Life Sciences Receives US FDA Breakthrough Device Designation for its Skin Biopsy-based Syn-One Test

CND Life Sciences has received FDA Breakthrough Device Designation for its Syn-One Test, designed to aid in diagnosing synucleinopathies in patients aged 40 years and above with neurological symptoms.

Global Pharma | 09/10/2025 | By Dineshwori |  285